Nectin Therapeutics Enters Global, Exclusive License Agreement With Immunome; Immunome Receives Exclusive Rights To Panel Of Antibodies Targeting An Undisclosed Target

7/25/24 7:41:52 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMNM alert in real time by email

Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies that are directed to a single undisclosed target. Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Nectin will receive an upfront payment and will be eligible for milestones and royalties.

Get the next $IMNM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMNM

Date	Price Target	Rating	Analyst
11/8/2024	$30.00	Overweight	Stephens
5/31/2024	$27.00	Overweight	Piper Sandler
4/30/2024	$24.00	Overweight	JP Morgan
4/15/2024	$35.00	Buy	Guggenheim
1/29/2024	$30.00	Outperform	Leerink Partners
12/19/2023	$12.00	Outperform	Wedbush
10/29/2021	$35.00	Overweight	Cantor Fitzgerald

More analyst ratings

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Immunome continues to advance its pipeline," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Topline data for the RINGSIDE Part B trial of AL102 is expected in the second half of 2025, and IND submissions for IM-1021 and IM-3050 are on track." "Our discovery team is focused on discovering ADCs that effectively pursue the novel targets we believe will define the next generation of transformative cancer therapie
11/13/24 4:05:00 PM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company
11/5/24 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $11.47 per share, the Compa
11/1/24 4:05:00 PM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th
3/28/24 4:02:00 PM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Reports Third Quarter 2023 Financial Results
- Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
11/9/23 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p
3/16/23 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care

$IMNM
Leadership Updates

Live Leadership Updates

Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
10/8/24 8:05:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an
7/9/24 7:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Appoints Phil Tsai as Chief Technical Officer
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug conjugates (ADCs). "Immunome is excited to add Phil to our management team as we advance our pipeline of differentiated targeted cancer therapies," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With the Phase 3 trial of AL102 for the treatment of desmoid tumors fully enrolled, two IND filings p
6/27/24 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care

Nectin Therapeutics Enters Global, Exclusive License Agreement With Immunome; Immunome Receives Exclusive Rights To Panel Of Antibodies Targeting An Undisclosed Target

Chat with this insight

Recent Analyst Ratings for $IMNM

$IMNM Market Insights

Live Market Insights